Nifurtimox

Hypersensitivity to nifurtimox or any of the excipients

Alcohol consumption during treatment

Genotoxicity has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents; a study in treated children with Chagas disease aged 7 months to 14 years demonstrated a 13-fold increase in chromosomal aberrations

Carcinogenicity has been observed in mice and rats treated chronically with nitrofuran agents which are structurally similar to nifurtimoximilar data have not been reported; association with carcinogenicity is unknown

May cause fetal harm when administered to pregnant females

May worsen conditions in patients with history of brain injury, seizures, psychiatric disease, or serious behavioral alterations; closely monitor these patients and in patients who develop neurological disturbances or psychiatric drug reactions during treatment

Cases of hypersensitivity reported; reaction may be induced by nifurtimox or an immune response triggered by Chagas disease during treatment; at first sign of serious hypersensitivity, discontinue treatment

Decreased appetite and weight loss were reported; patients can lose their appetite or experience nausea/vomiting which can result in weight loss; check body weight every 14 days and adjust dose accordingly

Nitrofuran derivatives may precipitate acute attacks of porphyria; administer tablets under close medical supervision in patients with porphyria